Oxford Immunotec Global Plc Revenue Growth Rates (OXFD), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Oxford Immunotec Global Plc  (NASDAQ: OXFD)
 

OXFD's Revenue Growth by Quarter and Year

Oxford Immunotec Global Plc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

OXFD Revenue (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
4th Quarter December -
3rd Quarter September 19.44
2nd Quarter June 5.84
1st Quarter March 13.91
FY 39.19

OXFDs Annual Revenue
Oxford Immunotec Global Plc's Revenue in the fiscal year 2019 $ 73.71 millions
Oxford Immunotec Global Plc's Revenue in the fiscal year 2018 $ 59.75 millions
Oxford Immunotec Global Plc's Revenue in the fiscal year 2017 $ 103.08 millions
Oxford Immunotec Global Plc's Revenue in the fiscal year 2016 $ 86.08 millions
Oxford Immunotec Global Plc's Revenue in the fiscal year 2015 $ 62.78 millions




OXFD Revenue third quarter 2020 Y/Y Growth Comment
Oxford Immunotec Global Plc reported decrease in Revenue in the third quarter 2020 by -8.41% to $ 19.44 millions, from the same quarter in 2019.
The decrease in the third quarter 2020 Oxford Immunotec Global Plc's Revenue compares unfavorably to the Company's average Revenue increase of 10.44%.

Looking into third quarter 2020 results within In Vitro & In Vivo Diagnostic Substances industry 12 other companies have achieved higher Revenue growth. While Oxford Immunotec Global Plc' s Revenue decline of -8.41% ranks overall at the positon no. 2855 in the third quarter 2020.


OXFD Revenue ( Y/Y Growth %) 2020
 2019 2018 2017
4th Quarter December - 17.83 % -38.59 % 5.57 %
3rd Quarter September -8.41 % 32.21 % -47.26 % 16.55 %
2nd Quarter June -70.19 % -33.19 % 12.25 % 36.4 %
1st Quarter March -5.95 % -30.79 % -0.65 % 25.72 %
FY   - -10.23 % -20.35 % -

Financial Statements
Oxford Immunotec Global Plc's third quarter 2020 Revenue $ 19.44 millions OXFD's Income Statement
Oxford Immunotec Global Plc's third quarter 2019 Revenue $ 21.22 millions Quarterly OXFD's Income Statement


OXFD Revenue (Quarter on Quarter Growth %)

 2020
 2019 2018 2017
4th Quarter December - -14.66 % -4.24 % -17.75 %
3rd Quarter September 232.81 % 8.32 % -45.26 % 16.5 %
2nd Quarter June -58.02 % 32.45 % 37.2 % 21.43 %
1st Quarter March -23.19 % -3.77 % -14.62 % -9.28 %
FY (Year on Year)   - -10.23 % -20.35 % -


Back to OXFD Growth rate Comparisons >> Back to OXFD Growth rate Comparisons >>


Revenue third quarter 2020 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #13
Healthcare Sector #472
Overall #2855

Revenue Y/Y Growth Statistics
High Average Low
59.84 % 10.44 % -70.21 %
(Sep 30 2016)   (Jun 30 2020)
Revenue third quarter 2020 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #13
Healthcare Sector #472
Overall #2855
Revenue Y/Y Growth Statistics
High Average Low
59.84 % 10.44 % -70.21 %
(Sep 30 2016)   (Jun 30 2020)

Revenue by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Oxford Immunotec Global Plc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
233.09 % 10.76 % -58.05 %
(Sep 30 2020)  


OXFD's III. Quarter Q/Q Revenue Comment
Oxford Immunotec Global Plc achieved in the III. Quarter 2020 above company average sequential Revenue doubling of 232.81%, to $ 19.44 millions, from $5.84 millions in the second quarter.
OXFD is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within In Vitro & In Vivo Diagnostic Substances industry only one company achieved higher sequential Revenue growth. While Oxford Immunotec Global Plc's Revenue growth quarter on quarter, overall rank is 149.


Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #2
Healthcare Sector #55
Overall #149
Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #2
Healthcare Sector #55
Overall #149
Revenue Q/Q Growth Statistics
High Average Low
233.09 % 10.76 % -58.05 %
(Sep 30 2020)  


OXFD's III. Quarter Q/Q Revenue Comment
Oxford Immunotec Global Plc achieved in the III. Quarter 2020 above company average sequential Revenue doubling of 232.81%, to $ 19.44 millions, from $5.84 millions in the second quarter.
OXFD is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within In Vitro & In Vivo Diagnostic Substances industry only one company achieved higher sequential Revenue growth. While Oxford Immunotec Global Plc's Revenue growth quarter on quarter, overall rank is 149.


Oxford Immunotec Global Plc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2020)		 12 Months Ending
(Jun 30 2020)		 12 Months Ending
(Mar 31 2020)		 12 Months Ending
(Dec 31 2019)		 12 Months Ending
(Sep 30 2019)
Cumulative Revenue 12 Months Ending $ 57.30 $ 59.08 $ 72.83 $ 73.71 $ 70.96
Y / Y Revenue Growth (TTM) -19.26 % -10.21 % -3.56 % -10.22 % -22.67 %
Year on Year Revenue Growth Overall Ranking # 3375 # 728 # 50 # 548 # 2948
Seqeuential Revenue Change (TTM) -3.02 % -18.88 % -1.19 % 3.87 % 7.86 %
Seq. Revenue Growth (TTM) Overall Ranking # 910 # 1468 # 551 # 120 # 330


Cumulative Revenue growth Comment
Oxford Immunotec Global Plc's cumulative 12 months Revenue continue to fall, but on the faster rate at -19.26% year on year, at Sep 30 2020 compare to the -10.21% decrease at Jun 30 2020. If the Oxford Immunotec Global Plc's fiscal year would end at Sep 30 2020, annual Revenue would be $57 millions.

In the Healthcare sector 445 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 728 to 3375.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 6
Healthcare Sector # 446
Overall # 3375

Revenue TTM Y/Y Growth Statistics
High Average Low
49.82 %
 8.96 %
-57.22 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 6
Sector # 188
S&P 500 # 910
Cumulative Revenue growth Comment
Oxford Immunotec Global Plc's cumulative 12 months Revenue continue to fall, but on the faster rate at -19.26% year on year, at Sep 30 2020 compare to the -10.21% decrease at Jun 30 2020. If the Oxford Immunotec Global Plc's fiscal year would end at Sep 30 2020, annual Revenue would be $57 millions.

In the Healthcare sector 445 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 728 to 3375.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 6
Healthcare Sector # 446
Overall # 3375

Revenue TTM Y/Y Growth Statistics
High Average Low
49.82 %
8.96 %
-57.22 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 6
Sector # 188
S&P 500 # 910




Other Revenue Growth
In Vitro & In Vivo Diagnostic Substances Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
OXFD's Revenue Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Sep 30 2020 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2020
Ensign Group Inc-0.21%$ -0.208 millions
Crh Medical Corporation-0.21%$ -0.215 millions
Radnet Inc -0.24%$ -0.237 millions
Tenet Healthcare Corp-0.24%$ -0.241 millions
Prestige Consumer Healthcare Inc -0.27%$ -0.272 millions
Establishment Labs Holdings Inc -0.42%$ -0.420 millions
Cocrystal Pharma Inc -0.61%$ -0.610 millions
American Renal Associates Holdings Inc -0.82%$ -0.823 millions
Rockwell Medical inc -0.83%$ -0.826 millions
Tactile Systems Technology Inc -1.05%$ -1.048 millions
Icon Plc-1.23%$ -1.226 millions
American Bio Medica Corporation-1.34%$ -1.341 millions
Transmedics Group Inc -1.58%$ -1.582 millions
Boston Scientific Corporation-1.77%$ -1.773 millions
Bruker Corporation-1.86%$ -1.861 millions
Orthofix Medical Inc -2.21%$ -2.215 millions
Encision Inc -2.29%$ -2.288 millions
Integra Lifesciences Holdings Corp-2.34%$ -2.338 millions
Neurometrix Inc -2.48%$ -2.480 millions
Lifevantage Corp-2.49%$ -2.492 millions
Macrogenics Inc -2.60%$ -2.604 millions
Surgalign Holdings Inc -2.70%$ -2.704 millions
Alimera Sciences Inc-2.93%$ -2.934 millions
Fortress Biotech Inc -3.04%$ -3.039 millions
Teleflex Incorporated-3.09%$ -3.088 millions
Adm Tronics Unlimited Inc -3.10%$ -3.105 millions
Bausch Health Companies Inc -3.21%$ -3.214 millions
Atricure Inc -3.28%$ -3.280 millions
Aspira Women s Health inc -3.58%$ -3.580 millions
Electromed Inc -3.59%$ -3.593 millions


About Oxford Immunotec Global Plc Revenue Growth Rates (OXFD), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.